新型小分子药物在治疗慢性淋巴细胞白血病中的研究进展

发布时间：2018-03-28 13:05

  本文选题：慢性淋巴细胞白血病　切入点：BTK抑制剂　出处：《中国实验血液学杂志》2017年01期

【摘要】：慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)是西方国家最常见的成人白血病,以CD5~+CD19~+CD23~+的B淋巴细胞在外周血、骨髓和淋巴结中的聚集为特征。在过去的20年里,CLL的治疗发生了一个戏剧性的变化,患者治疗后完全缓解率(complete responses,CR)由最初的5%提高到了现在的40%-50%。这一进步归因于联合化学免疫疗法对慢性淋巴细胞白血病患者骨干的治疗,尤其近5年来一些新型药物的爆发式出现,给复发/难治患者和细胞遗传学异常患者的治疗提供了十分有效的方案。本文主要针对已被批准或已用于临床治疗CLL的新型小分子药物最新研究进展作一综述,讨论的主要药物包括布鲁顿酪氨酸激酶抑制剂(ibrutinib),P13K抑制剂(idelalisib),Syk抑制剂,BCL-2抑制剂等。
[Abstract]:Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in western countries, with B lymphocytes from CD5 ~ CD19 ~ CD23 ~ in peripheral blood. The aggregation of bone marrow and lymph nodes has been characterized by a dramatic change in the treatment of CLL over the past 20 years. After treatment, the complete response rate (CR) increased from the initial 5% to the present 40%. This progress is attributed to the treatment of the backbone of patients with chronic lymphocytic leukemia by combined chemotherapy, especially the explosive appearance of some new drugs in the past five years. It provides a very effective scheme for the treatment of recurrent / refractory patients and patients with cytogenetic abnormalities. This article reviews the latest research progress of new small molecular drugs that have been approved or have been used in clinical treatment of CLL. The main drugs discussed include Bruton tyrosine kinase inhibitor P13K P13K and Syk inhibitor BCL-2.
【作者单位】： 兰州军区兰州总医院全军血液病中心;
【分类号】：R733.72
，

本文编号：1676445